Half-year report · HY
6523.TEDINET S100X235
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥173.4bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥361.6bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥173.9bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥10.4bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥941m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥18.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥559m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥692m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥525.8bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥532.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥525.4bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥379.8bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥391.3bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥146.0bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥141.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥127.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥146.7bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥141.6bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥127.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥39.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥33.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥12.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.9bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥17.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-4.42 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥83.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥32.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-4.42 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥82.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥32.42 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 27.9% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.3% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.2bn |
| Diabetes Managementreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥48.7bn |
| Diabetes Managementreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥48.7bn |
| Diabetes Managementreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥9.3bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥59.1bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥59.1bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Healthcare Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥62.7bn |
| Healthcare Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥62.7bn |
| Healthcare Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥170.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥170.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥13.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.3bn |
| Diabetes Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 753
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation and amortization operating expenses IFRS | Prior1InterimDuration | 14310000000 | JPY |
| Impairment losses pl IFRS | Prior1InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | 56000000 | JPY |
| Impairment losses pl IFRS | Prior1InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | Prior1InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | Prior1InterimDuration_ReportableSegmentsMember | 56000000 | JPY |
| Impairment losses pl IFRS | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | Prior1InterimDuration | 56000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | 48678000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | 62653000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 59142000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReportableSegmentsMember | 170474000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReconcilingItemsMember | 2901000000 | JPY |
| Revenue from external customers IFRS | InterimDuration | 173375000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration_ReportableSegmentsMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration | － | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | 48678000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | 62653000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 59142000000 | JPY |
| Revenue IFRS | InterimDuration_ReportableSegmentsMember | 170474000000 | JPY |
| Revenue IFRS | InterimDuration_ReconcilingItemsMember | 2901000000 | JPY |
| Revenue IFRS | InterimDuration | 173375000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | 9328000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | 2970000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 1317000000 | JPY |
| Operating profit loss IFRS | InterimDuration_ReportableSegmentsMember | 13616000000 | JPY |
| Operating profit loss IFRS | InterimDuration_ReconcilingItemsMember | -3237000000 | JPY |
| Operating profit loss IFRS | InterimDuration | 10378000000 | JPY |
| Finance income IFRS | InterimDuration | 169000000 | JPY |
| Finance costs IFRS | InterimDuration | 9606000000 | JPY |
| Profit loss before tax IFRS | InterimDuration | 941000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | 2224000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | 5205000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 5615000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_ReportableSegmentsMember | 13044000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_ReconcilingItemsMember | 302000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration | 13347000000 | JPY |
| Impairment losses pl IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 1000000 | JPY |
| Impairment losses pl IFRS | InterimDuration_ReportableSegmentsMember | 1000000 | JPY |
| Impairment losses pl IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | InterimDuration | 1000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-12 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |